^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AGS62P1

    i
    Other names: AGS62P1, AGS 62P1, ASP1235
    Company:
    Astellas
    Drug class:
    Microtubule inhibitor, FLT3-targeted antibody-drug conjugate
    Related drugs:
    2years
    Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. (PubMed, Oncotarget)
    Similarly, the combination of ASP1235, venetoclax and azacitidine showed a superior anti-tumor effect in a THP-1 xenograft model without obvious body weight loss. These findings provide supportive evidence that the triple combination of ASP1235, venetoclax and azacitidine would improve the clinical outcome of ASP1235 monotherapy and venetoclax plus azacitidine regimen in AML patients.
    Preclinical • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • FLT3 expression
    |
    Venclexta (venetoclax) • azacitidine • AGS62P1